Relx PLC is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, hedge fund interest, and favorable analyst ratings, despite short-term overbought technical indicators. The company's recent partnerships and innovations in the insurance sector further strengthen its long-term growth potential.
The MACD histogram is positive and expanding, indicating bullish momentum. RSI is at 84.333, signaling an overbought condition, which may suggest a short-term pullback. Moving averages are converging, showing potential for a breakout. Key resistance levels are at 36.028 and 36.913, while support levels are at 34.596 and 33.163.

Relx's partnership with Agenium enhances its offerings in the insurance sector, providing real-time risk scoring and operational efficiency improvements. Hedge funds are significantly increasing their holdings, with a 147.40% increase in buying activity over the last quarter. Analysts have upgraded the stock, citing resilience to AI concerns and valuation opportunities.
The RSI indicates an overbought condition, which may lead to a short-term pullback. Options data shows a higher put volume compared to call volume, suggesting cautious sentiment in the short term.
Financial data is unavailable for analysis, but analysts have highlighted resilience in Q4 earnings despite AI concerns, with no discernible impact on results or guidance.
Analysts are generally positive on Relx. Citi upgraded the stock to Buy, citing valuation opportunities. BofA raised its price target to $47.20, highlighting resilience in earnings. Morgan Stanley maintains an Overweight rating, despite lowering the price target slightly.